GLP-1 Weight Loss Medications: Complete Guide
Everything you need to know about semaglutide, tirzepatide, and the next generation of obesity drugs — efficacy, side effects, costs, and how to access them.
What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of injectable (and increasingly oral) medications that mimic the action of glucagon-like peptide-1, a hormone secreted by cells in the small intestine in response to eating. Originally developed for type 2 diabetes management, their dramatic weight loss effects led to dedicated obesity indications from the FDA.
The mechanism is multifaceted: GLP-1 drugs slow the rate at which food leaves the stomach (gastric emptying), reduce appetite signals in the hypothalamus, and stimulate insulin release while suppressing glucagon. The net result is significant, sustained caloric reduction without the willpower battles associated with traditional dieting.
Drug-by-Drug Breakdown
Semaglutide — Wegovy & Ozempic (Novo Nordisk)
Wegovy (Weight Loss)
FDA 2021 2.4 mg weekly injection. Average 15% weight loss in STEP trials. Indicated for BMI ≥ 30 or ≥ 27 with comorbidity. Monthly cost ~$1,350.
Ozempic (Diabetes)
FDA 2017 Up to 2.0 mg weekly. Widely prescribed off-label for weight loss. Lower dose than Wegovy but similar mechanism. Monthly cost ~$900–$1,000.
Semaglutide's landmark SELECT trial (2023, n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with obesity and established cardiovascular disease — a breakthrough that led to expanded coverage under Medicare Part D in 2024.
Tirzepatide — Zepbound & Mounjaro (Eli Lilly)
Zepbound (Weight Loss)
FDA 2023 Dual GLP-1/GIP agonist. 15 mg weekly injection. Average 20–22% weight loss in SURMOUNT trials — superior to any prior medication. Monthly cost ~$1,060.
Mounjaro (Diabetes)
FDA 2022 Same molecule as Zepbound. Up to 15 mg weekly. Broadly used off-label for weight management in type 2 diabetes patients.
The SURMOUNT-1 trial (n=2,539) showed that participants on tirzepatide 15 mg lost a mean 22.5% of body weight — the highest efficacy ever demonstrated for a pharmacologic obesity treatment. Approximately 57% of participants achieved ≥ 20% weight loss, a threshold previously associated only with bariatric surgery.
Older GLP-1 Agents
| Drug | Brand | Dosing | Avg. Loss | Notes |
|---|---|---|---|---|
| Liraglutide | Saxenda | 3 mg/day injection | ~8% | FDA-approved for obesity since 2014; daily dosing less convenient |
| Exenatide | Byetta, Bydureon | Weekly injection | ~3–5% | Primarily diabetes use; modest weight loss |
Emerging Medications (Pipeline)
The next wave of obesity pharmacology is already in late-stage trials:
- Retatrutide (Eli Lilly): Triple agonist (GLP-1/GIP/glucagon). Phase 2 data showed up to 24.2% weight loss at 48 weeks — potentially surpassing tirzepatide.
- Orforglipron (Eli Lilly): Oral GLP-1 pill (non-peptide). Phase 3 results showed ~15% weight loss — matching injections without needles.
- Cagrilintide + semaglutide (CagriSema, Novo Nordisk): Combination of amylin analog and semaglutide. Phase 3 data showed ~22% weight loss.
- Amycretin (Novo Nordisk): Oral GLP-1/amylin combination. Phase 1 data showed 13% loss in 12 weeks — remarkable for an oral agent.
Side Effects and Safety Profile
GLP-1 medications have a well-characterized safety profile built from years of use in type 2 diabetes. The most common side effects are gastrointestinal and dose-dependent:
- Nausea: Affects 40–50% of patients, especially during dose escalation. Usually resolves within 4–8 weeks.
- Vomiting: Less common than nausea; typically manageable with slower dose titration.
- Diarrhea / Constipation: Occur in 20–30% of patients.
- Injection site reactions: Mild and transient; occur with all injectable forms.
Serious adverse events are uncommon. Pancreatitis has been reported rarely. GLP-1 drugs carry a boxed warning for thyroid C-cell tumors based on rodent studies, though human relevance remains unestablished. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Cost and Access
The high list price of GLP-1 drugs remains the primary access barrier for millions of patients. Without insurance, monthly costs range from $1,000 to $1,500. Options to reduce out-of-pocket cost include:
- Manufacturer savings cards: Novo Nordisk and Eli Lilly offer savings programs that can reduce cost to $25–$99/month for commercially insured patients.
- Medicare Part D: As of 2024, semaglutide is covered for cardiovascular risk reduction in eligible beneficiaries. Full obesity coverage expansion is expected in 2026.
- Compounded semaglutide: Available during FDA shortage periods but quality and safety are not guaranteed. The FDA has warned about compounded versions.
- Prior authorization: Required by most plans. Your provider will need to document BMI, failed lifestyle interventions, and weight-related comorbidities.
Is Surgery a Better Option for You?
Compare GLP-1 medications versus bariatric surgery with our detailed guide.
View Surgery Guide →